Copyright © 2019 SpinalCyte. All rights reserved.

Website Design by Blue Heron Support

Chronic Lower Back Pain afflicts an estimated 33 million people annually in the U.S. Over 7 million of those people suffer from Degenerative Disc Disease. Aging baby boomers may double those numbers in the next two decades. At SpinalCyte, we are the clinical stage world leader in patented fibroblast cell therapy to treat Degenerative Disc Disease.

 

Back pain is strongly associated with degeneration of the intervertebral disc. Disc degeneration, although in many cases asymptomatic, is also associated with sciatica and disc herniation or prolapse. It alters disc height and the mechanics of the rest of the spinal column, adversely affecting the behavior of other spinal structures such as muscles and ligaments. In the long term, it can lead to spinal stenosis, a major cause of pain and disability in the elderly. Degenerated disc incidence is rising with current demographic changes and an increased aged population.

Recent Developments

October 23, 2019

CEO/CFO Magazine Interviews SpinalCyte CEO,

Pete O'Heeron  Read More

October 21, 2019

SpinalCyte to Present at BIO Investor Forum  

Read More

 

October 15, 2019

SpinalCyte Announces New Japanese Patent 

Read More

 

September 19, 2019

SpinalCyte Announces New International Patent 

Read More

 

June 5, 2019

SpinalCyte to Present at Boao Forum in Qingdao, China  Read More

May 15, 2019

SpinalCyte Launches Initiative to Highlight Advances in Fibroblast Technology  Read More

March 28, 2019

SpinalCyte to Provide Clinical Trial Update at the 2019 International Society for the Advancement of Spine Surgery Annual Meeting  Read More

 

March 18, 2019

SpinalCyte to Present at China Focus @ Europe Vienna, Austria  Read More

 

March 11, 2019

SpinalCyte Announces Two New Patents  Read More

 

February 4, 2019

SpinalCyte to Present at the 2019 BIO CEO & Investor Conference  Read More

 

January 8, 2019

SpinalCyte Announces New International Patent  

Read More